Non-Invasive Eosinophilic Gastritis Diagnostic
Summary
Non-Invasive Eosinophilic Gastritis Diagnostic
Overview
Diagnostic assay to monitor or diagnose Eosinophilic Gastritis (EG) through detection of the presence and level of biomarkers in the blood of a patient. The use of a blood assay reduces the need of tissue biopsy of the esophagus while screening, diagnosing, monitoring Eosinophilic Esophagitis (EoE).
This technology offers an opportunity to diagnose and monitor EoE through blood testing instead of sedation and esophageal biopsy. The blood biomarker testing allows monitoring of the disease and status without the need to visualize and biopsy through an invasive procedure. These advantages include improved accuracy, earlier diagnosis, better monitoring, and more effective treatment.
Applications
Diagnostic assay to monitor or diagnose Eosinophilic Gastritis (EG) through detection of the presence and level of biomarkers in the blood of a patient. The use of a blood assay reduces the need of tissue biopsy of the esophagus while screening, diagnosing, monitoring Eosinophilic Esophagitis (EoE)
Value Proposition
This technology offers an opportunity to diagnose and monitor EoE through blood testing instead of sedation and esophageal biopsy. The blood biomarker testing allows monitoring of the disease and status without the need to visualize and biopsy through an invasive procedure. These advantages include improved accuracy, earlier diagnosis, better monitoring, and more effective treatment.
Market Overview
Prevalence of EOE in the US is approximately 57-90 / 100K people. Slightly lower in the European market at 30-50 / 100K.
The Incidence is 5-10 / 100K people.
Investigator
Dr. Mark Rothenberg
Dr. Tetsuo Shoda
